Aspecthera

Aspecthera is a pre-clinical stage pharmaceutical company developing a non-invasive eye-drop therapy for diabetic retinopathy, a leading cause of vision loss on a global scale. The company was spun-out of the University of Tasmania in 2024 with support from UTAS InVent (Innovation Ventures). Our patient-centric candidate eye-drop therapy is highly differentiated from the current standard-of-care, which involves a burdensome intravitreal (eye injection) treatment paradigm, and also shows promise for early-stage disease intervention filling a large unmet medical need.